BSI-730

BSI-730 is a novel bispecific antibody drug conjugate developed by Biosion for oncology indications. It targets both HER2 (Receptor tyrosine-protein kinase erbB-2) and PD-L1 (Programmed death-ligand 1), functioning as a modulator of these proteins. The drug was identified using Biosion's proprietary SynTracer HT-endocytosis platform and is designed to combine the anti-tumor effects of HER2 inhibition with immune checkpoint blockade via PD-L1. Preclinical data indicate that BSI-730 has binding affinity to HER2 comparable to trastuzumab and similar bioactivity to parental anti-PD-L1 antibodies in terms of PD-L1 binding and PD-1/PD-L1 blocking[1][3][4]. Its primary therapeutic area is cancer, specifically neoplasms.